Comparison

Polyphyllin I European Partner

Item no. TMO-T3895-100mg
Manufacturer TargetMol
CASRN 50773-41-6
Amount 100 mg
Quantity options 100 mg 10 mg 1 mg 200 mg 25 mg 500 mg 50 mg 5 mg
Category
Type Inhibitors
Specific against other
Purity 0,9936
Smiles [H][C@]12C[C@@]3([H])[C@]4([H])CC=C5C[C@H](CC[C@]5(C)[C@@]4([H])CC[C@]3(C)[C@@]1([H])[C@H](C)[C@@]1(CC[C@@H](C)CO1)O2)O[C@]1([H])O[C@H](CO)[C@@H](O[C@]2([H])O[C@@H](CO)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@]1([H])O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O
ECLASS 10.1 32160490
ECLASS 11.0 32160490
UNSPSC 12000000
Shipping Condition Cool pack
Available
Manufacturer - Targets
mTOR|||Autophagy|||Apoptosis|||PDK|||JNK|||Akt
Shipping Temperature
Cool pack
Storage Conditions
-20
Molecular Weight
855.02
Description
Polyphyllin D induces apoptosis via the mitochondrial apoptotic pathway as evidenced by decreased Bcl-2 expression levels, disruption of MMP and increased Bax, cytochrome C, and cleaved-caspase-3 levels. Polyphyllin D has an anti-angiogenic effect. Polyphyllin D has toxicity in human RBCs as well as its underlying mechanism for the hemolysis and eryptosis/erythroptosis. Polyphyllin D has strong anticancer activity, can overcome drug resistance in R-HepG2 cells and elicit programmed cell death via mitochondrial dysfunction.
Pathways
MAPK|||PI3K/Akt/mTOR signaling|||Apoptosis|||Cytoskeletal Signaling|||Autophagy

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 100 mg
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close